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Abstract
Orkney and Shetland, the population isolates that make up the Northern Isles of Scotland, are of particular interest to
multiple sclerosis (MS) research. While MS prevalence is high in Scotland, Orkney has the highest global prevalence, higher
than more northerly Shetland. Many hypotheses for the excess of MS cases in Orkney have been investigated, including
vitamin D deficiency and homozygosity: neither was found to cause the high prevalence of MS. It is possible that this excess
prevalence may be explained through unique genetics. We used polygenic risk scores (PRS) to look at the contribution of
common risk variants to MS. Analyses were conducted using ORCADES (97/2118 cases/controls), VIKING (15/2000
cases/controls) and Generation Scotland (30/8708 cases/controls) data sets. However, no evidence of a difference in MS-
associated common variant frequencies was found between the three control populations, aside from HLA-DRB1*15:01 tag
SNP rs9271069. This SNP had a significantly higher risk allele frequency in Orkney (0.23, p value= 8 × 10–13) and Shetland
(0.21, p value= 2.3 × 10–6) than mainland Scotland (0.17). This difference in frequency is estimated to account for 6 (95%
CI 3, 8) out of 150 observed excess cases per 100,000 individuals in Shetland and 9 (95% CI 8, 11) of the observed 257
excess cases per 100,000 individuals in Orkney, compared with mainland Scotland. Common variants therefore appear to
account for little of the excess burden of MS in the Northern Isles of Scotland.
Introduction
Multiple sclerosis (MS) is the most common neurological
disability found in young adults in the Western world [1].
The disease is characterised by the inflammation and
chronic degeneration of the central nervous system, a
result of the destruction of the myelin sheath by the
individual’s immune system [2]. There is no definitive
explanation as to the reason for these immune attacks,
with genetic susceptibility and environmental factors both
contributing to MS risk [3, 4]. Although environmental
factors (for example, vitamin D, smoking, Epstein–Barr
viral exposure and body mass index (BMI)) are important
for MS risk [5–8], MS has a material genetic component:
broad-sense heritability has been estimated using twin,
sibling and half-sibling data as 0.64 (with a 95% con-
fidence interval (CI) of 0.36–0.76) [9]. Single-nucleotide
polymorphism (SNP) heritability has been estimated at
0.19 (95% CI 0.18, 0.20) [10]. MS arises most frequently
in genetically susceptible individuals who may have been
exposed to risk-associated environmental factors or sto-
chastic events [11]. A total of 233 genetic variants have
been identified as associated with MS susceptibility,
including 32 independent genetic effects within the major
histocompatibility (MHC) region on chromosome 6 [10].
The majority of these variants have an odds ratio (OR)
ranging from 1.05 to 1.20; however, the strongest asso-
ciation identified is with the HLA-DRB1*15:01 variant,
with an OR of 2.92 [10, 12].
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MS in the Northern Isles
The highest prevalence of MS in the world is found in the
Orkney islands in the North of Scotland, where prevalence
reaches 402 individuals per 100,000 [13]. The Shetland
islands, 50 miles north of Orkney, have a similarly high rate
of 295 individuals per 100,000 [13]. Mainland Scotland, for
comparison, has a prevalence of 145 individuals per
100,000 [13]. The prevalence of MS within these island
groups, in particular Orkney, is significantly higher than
what would be expected for a population of that latitude. A
number of previous studies have investigated the potential
cause of this excess of MS prevalence. Vitamin D defi-
ciency as a potential cause of MS was investigated by Weiss
et al. in 2016; however, plasma 25-hydroxyvitamin D was
found to be significantly higher in those on Orkney than in
mainland Scotland (mean 35.3 compared to 31.7 nmol/L).
Additionally, Orkney had a lower prevalence of severe
plasma 25-hydroxyvitamin D deficiency (of 6.6% compared
to 16.2% in mainland Scotland) [14]. Another study
investigated homozygosity, the inheritance of identical
haplotypes from both parents, in Orkney and Shetland [15].
Three measures of genome-wide homozygosity were gen-
erated for 88 MS patients and 178 matched controls and
assessed for association with MS. However, no association
was detected, and so consanguinity is not thought to be the
principal cause of the excess MS prevalence. However, it is
possible that this excess prevalence may be explained
genetically through the Northern Isles having a higher
proportion of common risk alleles. If the ancestors or
founders of the islands by chance had higher frequencies of
these risk alleles, this may cause additional cases of MS as
they would be segregating at higher frequencies today. This
idea was first suggested in 1981 by Compston, who implied
that Orcadians in general may have higher frequencies of
common risk variants [16].
Methods
Study participants
This research used 97 MS cases and 2118 controls from the
Orkney Complex Disease Study and the Northern Isles
Multiple Sclerosis Study (NIMS; collectively referred to as
ORCADES) as a sample of the Orkney population, 15 MS
cases and 2090 controls from the Viking Health Study
Shetland (VIKING) as a sample of the Shetland population
and 30 MS cases and 8708 controls from Generation
Scotland (GS) as a sample of the mainland Scotland
population. ORCADES, VIKING and GS are cross-sec-
tional, family-based cohorts that were established to become
platform resources for the study of complex disease in
Scotland, while the NIMS was established with the specific
aim of studying MS. Data collection and genotyping for
ORCADES, VIKING and GS has been fully described in
previous research papers but has been summarised along
with genotype and sample quality control (QC) steps in
Supplementary Table 1 [17–19]. A principal component
plot of the three cohorts can also be found in Supplementary
Fig. 1.
Selecting common risk variants for polygenic risk
score (PRS) calculation
A total of 127 key MS SNPs (Supplementary Table 2)
were compiled for PRS calculation, selected from the
2011 International Multiple Sclerosis Genetics Con-
sortium (IMSGC) genome-wide association study
(GWAS) [20] and the GWAS Catalogue [21–30]. The
SNPs selected from the 2011 IMSGC GWAS comprised a
group of 102 SNPs that were taken forward for replication
analysis in the original study. The 2011 IMSGC GWAS
was chosen in particular as this was the most recent large-
scale GWAS that the NIMS cohort did not contribute
towards. SNPs were included from the GWAS Catalogue
if the disease trait was listed as “multiple sclerosis” and
the SNPs originated from studies including only European
individuals. Additionally, only studies up to 2012 were
considered. Any SNPs originating from the 2011 IMSGC
GWAS, or from a study that included any individuals
from Orkney, were excluded from the GWAS Catalogue
search. Only SNPs with a p value <1 × 10−3 were con-
sidered, and SNPs were only included if they were present
in all three cohorts. Strict QC procedures were applied to
ensure that PRS results produced from these SNPs were
not biased or inaccurate and that subjects from the
Northern Isles had not contributed to the underlying
GWAS. These QC methods included removing SNPs
without a reported OR or risk allele, using inverse var-
iance meta-analyses to determine ORs and p values for
duplicated SNPs, and clumping SNPs for linkage dis-
equilibrium, using a cut-off threshold of r2= 0.25 within
a 200-kb window.
Calculating PRSs
PRSs were calculated for all individuals using the R
package PRSice (v1.25), which used the HRC-imputed
genotype dosage data for ORCADES, VIKING and GS as
the target SNP set, along with SNP effect sizes from the
original source (either the GWAS Catalogue or 2011
IMSGC GWAS). Risk scores were produced for the full
SNP set (n= 127), the SNP set without HLA-
DRB1*15:01 tag SNP rs9271069 (n= 126) and for
rs9271069 alone.
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Differentiating MS cases and controls
PRS were compared between cases and controls in each
data set. The three data sets were first standardised by z-
scoring the PRS to allow comparison between popula-
tions. Cases and controls were then compared within each
data set by fitting a generalised linear model with Gaus-
sian errors and an identity link function, using the R
function glm. Age, sex and the first two principal com-
ponents were included as covariates for all three popula-
tions. A meta-analysis for cases and a meta-analysis for
controls were performed to determine an estimate for the
overall case/control PRS.
Fitting a logistic regression model
Related individuals were removed before fitting the data to a
logistic regression model using a genomic kinship coefficient
threshold of 0.05. Following removal of related individuals,
cases and control numbers in each data set were as follows:
80/645 ORCADES individuals, 14/642 VIKING individuals,
and 29/ 8341 GS individuals. A logistic regression model was
fitted separately to each data set using the R function glm,
with MS disease status as the dependent variable, PRS as the
independent variable and age, sex, principal component 1 and
principal component 2 included as covariates. A null model
(with only covariates) was also fitted to each data set.
Determining how much MS variance is explained by
common risk variants
Logistic regression model results were used to assess how
much variance in MS risk common risk variants could
explain. Nagelkerke’s pseudo R2 value was calculated in R for
each data set and SNP group (full SNP set, SNP set without
rs9271069 and rs9271069 alone) using the model results.
Determining how successful common risk variants
are in predicting MS
To determine whether common risk variants could be a pre-
dictor of an individual’s MS status, the model results were
used to calculate a receiver operator characteristic curve
(ROC) and the area under this curve (AUC). ROCs were
plotted for each fitted model to assess how well the PRS with
covariates predicted MS disease status. The AUC was also
calculated to quantify the predictive ability of each model.
Comparing common variants between Orkney,
Shetland and mainland Scotland
To assess the difference in common risk variants between
each population, mean PRS between control individuals
were compared between GS, ORCADES and VIKING
using two-sample t tests. The frequency of each PRS SNP
was calculated in individuals without MS and compared
between GS, ORCADES and VIKING using a Pearson’s
chi-squared test.
Determining how much risk is explained by
common risk variants
An important aspect of this study was to estimate the con-
tribution of these variants to the excess MS prevalence in
the Northern Isles. This was done by determining the
expected difference in prevalence due to the differences in
frequencies of these variants between data sets. The
expected difference in prevalence was then compared to the
observed difference in prevalence seen in mainland Scot-
land, Orkney and Shetland. First, the difference in means
between (a) GS and VIKING and (b) GS and ORCADES
was calculated. Only control individuals were included in
this calculation. The differences in means were then mul-
tiplied by the beta value produced from the meta-analysis of
each of the data set’s models with covariates, to give the
expected odds values. The expected odds values produced
is the proportion of the odds that could be attributed to
difference in mean PRS between populations. Thus, given
the frequencies of the common risk variants that have been
looked at in the PRS, these values would be the expected
increase in MS risk for the Northern Isles populations, using
GS (Glasgow/Dundee) as the baseline. This would reflect
the genetic difference due to common risk variants. To
determine how this expected difference in MS risk
explained by common risk variants compared to the
observed MS risk between populations, the expected dif-
ferences in odds values were compared to the observed
difference in odds values. Observed MS prevalence data
were obtained from Visser et al. [13] using Aberdeen City
for Mainland Scotland. ORs were calculated using con-
tingency tables and converted into log of ORs for com-
parison with the expected values.
Results
Data summary
The demographic characteristics for study individuals can
be found in Table 1.
Comparing PRS in MS cases and controls
MS cases have statistically significantly higher polygenic
scores than MS controls using the full SNP set in
each population (Fig. 1 and Supplementary Table 3, with
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p values: ORCADES, 5.63 × 10–9; GS, 7.6 × 10–4;
VIKING, 2.82 × 10–2), validating the use of PRS.
When rs9271069 is removed, only cases in ORCADES
(p value= 1.8 × 10–5) and GS (p value= 5.67 × 10–3) are
statistically different. When rs9271069 is considered
alone, only ORCADES cases and controls are statistically
different (p value= 1.02 × 10–5), with slight significance
seen in GS (p value= 0.045). This pattern of significance
reflects the number of cases found in each data set:
ORCADES (significant in all three comparisons) has 97
cases, GS (significant in two comparisons) has 30 cases,
and VIKING (significant in the main comparison only)
has 15 cases.
How much variance PRS explain and their ability to
predict MS
To determine how much MS variance is explained by
common risk variants, a logistic regression model was fitted
separately to each data set, with MS status as the dependent
variable, PRS as the independent variable, and age, sex, PC
1 and PC2 as covariates. Nagelkerke’s pseudo R2 and AUC
values were calculated using the model results to determine
how much variance the risk scores explained and how
successful they were in predicting MS.
The full model results, including R2 and AUC values, can
be found in Table 2. The models fitted using the full SNP
set (n= 127) with covariates resulted in the highest R2
values in each population (VIKING R2= 0.075,
ORCADES R2= 0.070, GS R2= 0.069). In comparison, the
null model (containing only covariates) for each population
resulted in an R2 value of 0.045 for VIKING, 0.019 for
ORCADES and 0.038 for GS.
The models fitted using the full SNP set (n= 127) with
covariates also resulted in the highest AUC values for each
population: GS AUC= 0.77 (95% CI 0.68–0.85), VIKING
AUC= 0.76 (0.65–0.87) and ORCADES AUC= 0.70
(0.65–0.76). In comparison, the null model (containing
only covariates) for each population resulted in AUC
values of 0.71 (0.61–0.81) for GS, 0.70 (0.59–0.81) for
VIKING and 0.60 (0.54–0.66) for ORCADES. The ROC
curves for each population and PRS can be found in Sup-
plementary Fig. 1.
Do MS common risk variants differ in frequency
between mainland Scotland and the Northern Isles?
When we compared the control populations from each data
set, a statistically significant difference between GS and
both ORCADES and VIKING was seen for the full SNP set
(Table 3). When rs9271069 was removed from the SNP set,
there was no significant difference detectable between any
of the control populations. When rs9271069 was looked at
alone, a statistical difference was seen when comparing all
populations. Supplementary Table 2 provides the risk allele
frequency (RAF) of each PRS SNP, calculated using control
individuals within each population, along with Pearson’s
chi-squared results comparing RAF between populations.
The SNP with the highest associated MS risk, HLA-
DRB1*15:01 tag SNP rs9271069 (OR= 2.77), had a sig-
nificantly higher frequency in Orkney controls (RAF=
0.23) and Shetland controls (RAF= 0.21) than mainland
Scotland controls (RAF= 0.17: respective p values of 8 ×
10–13 and 2.3 × 10–6).
How much of the excess MS cases in the Northern
Isles is caused by common risk variants?
To determine the contribution of common risk variants to
excess MS cases in the Northern Isles, a comparison was
made between the calculated expected odds and the
observed odds seen from MS prevalence data (Table 4). In
Shetland, common risk variants account for 9 (95% CI 5,
14) out of 150 observed excess cases per 100,000
Table 1 Summary statistics for
ORCADES, VIKING and
Generation Scotland.
Population Sex Count Mean age (standard deviation)
Case Control Total Case Control Total
ORCADES M 28 843 871 54.30 (9.40) 54.85 (15.20) 54.83 (15.04)
F 69 1275 1344 49.13 (12.36) 53.85 (15.54) 53.61 (15.43)
All 97 2118 2215 50.64 (11.76) 54.25 (15.41) 54.09 (15.28)
VIKING M 3 839 842 60.95 (8.83) 51.34 (15.47) 51.37 (15.46)
F 12 1251 1263 53.73 (13.10) 48.93 (15.06) 48.97 (15.05)
All 15 2090 2105 55.28 (12.39) 49.90 (15.27) 49.93 (15.26)
Generation Scotland M 5 3574 3579 45.80 (7.92) 45.89 (15.26) 45.89 (15.26)
F 25 5134 5159 50.80 (9.53) 46.48 (14.78) 46.50 (14.76)
All 30 8708 8738 49.97 (9.35) 46.23 (14.98) 46.25 (14.97)
Count and mean age for the Orkney Complex Disease Study (ORCADES), Viking Health Study – Shetland
(VIKING) and Generation Scotland cohorts, split by gender and multiple sclerosis (MS) disease status.
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individuals. The majority of the expected odds is from the
HLA-DRB1*15:01 tag SNP rs9271069, which contributes
an equivalent of 6 cases (95% CI 3, 8) per 100,000 indi-
viduals. In Orkney, all the expected excess genetic odds are
due to HLA-DRB1*15:01 tag SNP rs9271069, which
accounts for 9 cases (95% CI 8, 11) of the observed 257
excess cases per 100,000 individuals. Considering the
populations of Orkney (22,000) and Shetland (23,000), the
Fig. 1 Forest plots of z-scored polygenic risk scores (PRSs) for
multiple sclerosis cases and controls in Generation Scotland,
ORCADES and VIKING. PRS calculated using three SNP sets are
used for comparison: A. the full SNP set (n= 127), B. the SNP set
without HLA-DRB1*15:01 tag SNP rs9271069 (n= 126), and C. a
risk score for rs9271069 alone.
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differences in allele frequencies of common variants can
thus only explain the equivalent of about two excess cases
of MS in each archipelago.
Study limitations
A major limitation of this study was the use of the IMSGC
2011 GWAS as a key contributor to the SNP data on which
the PRS calculation was based. It was preferable to use the
most recent, large-scale GWAS for this study; however, the
IMSGC 2011 GWAS is the most recent GWAS that did not
include data generated from individuals in the NIMS. While
using an older GWAS may result in some loss of power, we
have included the most important common susceptibility
alleles within the PRS calculation in this study. We also
recognise that this PRS uses a limited number of strong-
effect SNPs selected from multiple sources; while this does
not bias our results, there are many ways to construct a PRS
and this score could have been made in other ways by other
researchers at other times.
The sample size was a further limitation to this study.
Orkney and Shetland are both relatively small populations
(approximately 22,000 individuals in Orkney and 23,000
individuals in Shetland) and will therefore yield small
Table 2 Logistic regression results for predicting MS risk using polygenic risk scores.
Model Estimate SE t value Pr(>|t|) Sig. AIC R2 AUC AUC SE
VIKING: Full SNP set 0.59 0.26 2.26 0.024 * 167.73 0.075 0.762 0.055
VIKING: HLA only 0.31 0.23 1.37 0.172 170.99 0.055 0.706 0.066
VIKING: SNP set without HLA 0.51 0.27 1.86 0.063 169.27 0.066 0.753 0.047
VIKING: Null model 170.72 0.045 0.696 0.056
ORCADES: Full SNP set 0.60 0.11 5.58 2.36 × 10–8 *** 696.36 0.070 0.705 0.029
ORCADES: HLA only 0.40 0.09 4.31 1.60 × 10–5 *** 710.31 0.047 0.658 0.032
ORCADES: SNP set without HLA 0.45 0.11 4.11 3.98 × 10–5 *** 710.85 0.046 0.666 0.030
ORCADES: Null model 725.93 0.019 0.600 0.029
Generation Scotland: Full SNP set 0.63 0.19 3.40 0.001 *** 372.32 0.069 0.765 0.042
Generation Scotland: HLA only 0.32 0.16 1.96 0.050 380.24 0.048 0.731 0.045
Generation Scotland: SNP set
without HLA
0.53 0.19 2.81 0.005 ** 375.83 0.059 0.743 0.045
Generation Scotland: Null model 381.73 0.038 0.714 0.052
Logistic regression results for predicting MS risk using PRS, using ORCADES, VIKING and Generation Scotland cohorts. MS status was used as
the dependent variable in each model. Age, sex, principal component 1 and principal component 2 were used as covariates for all models. Three
separate PRS were used as the independent variable within each population: the full SNP set (n= 127 SNPs), the full SNP set without HLA-
DRB1*15:01 SNP rs9271069 (n= 126), and for the HLA-DRB1*15:01 SNP rs9271069 alone (n= 1). The null model was fitted without any PRS.
AIC values, Nagelkerke’s R2 values and AUC values (with associated standard error values) are also included for each model. For ease of
readability, only the coefficients of the genetic effect are shown. Thus, the coefficients of the covariates are not included. For the null models, only
the AIC, Nagelkerke’s R2 and AUC values are shown, as there is no genetic effect included within the null model. The Sig. column denotes the
signficance of the model estimate, where *** indicates a p value < 0.001, ** indicates a p value < 0.01 and * indicates a p value < 0.05.
Table 3 Comparison of PRS of MS controls between populations.
SNP set Population Controls (n) Mean PRS Population Controls (n) Mean PRS t test statistic p value
Full GS 8708 −0.047 ORCADES 2120 0.094 −5.78 8.34 × 10–9
GS 8708 −0.047 VIKING 2158 0.052 −4.05 5.26 × 10–5
ORCADES 2120 0.094 VIKING 2158 0.052 1.35 0.18
Without rs9271069 GS 8708 −0.01 ORCADES 2120 −0.033 1.03 0.3
GS 8708 −0.01 VIKING 2158 0.034 −1.77 0.08
ORCADES 2120 −0.033 VIKING 2158 0.034 −2.22 0.03
rs9271069 only GS 8708 −0.063 ORCADES 2120 0.151 −8.54 2.11 × 10–17
GS 8708 −0.063 VIKING 2158 0.07 −5.33 1.05 × 10–7
ORCADES 2120 0.151 VIKING 2158 0.07 2.53 0.01
Two-sided t test results comparing z-score transformed polygenic risk scores (PRS) of multiple sclerosis controls between Generation Scotland,
ORCADES and VIKING, using PRS produced using the full SNP set (n= 127), the SNP set without HLA-DRB1*15:01 tag SNP rs9271069 (n=
126) and a risk score for rs9271069 alone.
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numbers of MS cases, despite the high rates of MS in the
islands. However, the key analyses within this study were to
determine: (i) whether common risk variants differed
between the Northern Isles and mainland Scotland and (ii)
how these variants, as a group, contribute to the excess
burden of MS. Both of these analyses were conducted using
only control individuals and so were not affected by the
small number of cases.
Orkney and Shetland remain of key interest to MS: while it
is not possible to increase the case numbers within
ORCADES and VIKING, it was important to utilise
these cohorts given the unique genetics of these population
isolates.
Future work
The PRS used in this study included the strongest effect
allele from the MHC region, HLA-DRB1*15:01. The MHC
region is complex and includes other high-risk
variants (which may be in linkage disequilibrium with the
SNP included in this study). It is suggested that a future
study using PRS for MS focus on the MHC region
specifically.
Discussion
We found that common risk variants do not make a material
contribution towards the higher rates of MS in the Northern
Isles of Scotland. However, a small proportion of excess
risk can be attributed to a tag SNP for HLA-DRB1*15:01,
the major single genetic risk factor for MS (OR= 2.92).
This SNP has a significantly higher frequency in the
Northern Isles, particularly Orkney (RAF= 0.23), than
mainland Scotland (RAF= 0.17, p value= 8 × 10–13). Fre-
quencies for the tag SNP for HLA-DRB1*15:01 reported in
other cohorts appears to be similar to that in mainland
Scotland or lower: the ALFA Allele Frequency project
reports the frequency within European populations as 0.14
(sample size 33,120) [31]. It is possible that the frequency
of this allele is higher in the Northern Isles populations due
to the founders of Orkney and Shetland having higher fre-
quencies of the risk allele or it may have risen through
genetic drift in the past thousand years. Regardless, the
significantly higher frequency of this SNP in the Northern
Isles in comparison to both mainland Scotland and the
general European population suggests that it plays a modest
role in the prevalence of MS in the Northern Isles, even if
not the excess prevalence. We found that PRSs calculated
with the 127 most strongly associated MS risk variants
explained approximately 3–5% of variance. The 2019
IMSGC study, which analysed data from 47,429 MS cases
and 68,374 control subjects, estimated the heritability
attributable to all analysed common genetic variants at
19.2% [10]. Of this variance, 18% was explained by
genome-wide significant variants. Therefore, the heritability
of genome-wide significant variants was estimated at
approximately 3.5%, which aligns with the estimate from
Table 4 The contribution of common risk variants to excess MS prevalence in the Northern Isles.
Generation
Scotland
VIKING (95% CI) ORCADES
(95% CI)
Expected excess MS risk due to all common risk
variants
Log(OR) 0 0.06 (0.03, 0.09) 0.05 (0.02, 0.08)
Equivalent number
of cases
0 9 (5, 14) 8 (5, 11)
Expected excess MS risk due to common risk variants
without HLA-DRB1*1501 SNP rs9271069
Log(OR) 0 0.02 (0.00, 0.05) −0.01 (−0.04, 0.01)
Equivalent number
of cases
0 3 (0, 6) −1 (−3, 2)
Expected excess MS risk due to HLA-DRB1*1501
SNP rs9271069
Log(OR) 0 0.04 (0.02, 0.05) 0.06 (0.05, 0.07)
Equivalent number
of cases
0 6 (3, 8) 9 (8, 11)




Expected and observed excess MS risk (log of odds ratios) in both VIKING (Shetland; n controls= 2158) and ORCADES (Orkney; n controls=
2120) when compared to Generation Scotland (n controls= 8708). The difference between Generation Scotland and either ORCADES or VIKING
for expected MS risk differences are highlighted in bold. Expected log(OR) values were calculated from the logistic regression results by
multiplying the coefficient from the model with the mean PRS calculated from the full SNP set (n= 127), the full SNP set without HLA-
DRB1*15:01 SNP rs9271069 (n= 126) and HLA-DRB1*15:01 SNP rs9271069 alone (n= 1). Observed log of odds values were calculated from
the prevalence data found in the paper by Visser et al. The logistic regression model was fit to the cohort PRS data, using MS as the dependent
variable, PRS as the independent variable and age, sex and the first two principal components.
aTaken directly from the observed data.
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this study. Additionally, the variance within this study is
largely dominated by the increased frequency of the HLA-
DRB1*15:01 SNP in ORCADES, offsetting any gain from
including the additional SNPs with small (and uncertain)
effects. The predictive capacity of the PRSs for MS status
was calculated with an AUC of 0.77 (95% CI 0.68–0.85) in
GS, 0.76 (0.65–0.87) in VIKING and 0.70 (0.65–0.76) in
ORCADES. This is in line with the scores previously
published in literature. A 2016 study using 452 MS cases
with 103 common risk variants estimated the AUC to be
0.72 (95% CI 0.69, 0.75), which overlaps with the results
produced here [32]. MS is a heterogenous disease, and
while it is useful to see to what degree genetic risk scores
could aid in prediction, additional, especially rare, variants
or the incorporation of environmental factors into prediction
models will be required to improve risk prediction. The
cause of the excess MS prevalence in the Northern Isles
remains mostly unexplained and is still a case for investi-
gation: it can likely be attributed to several factors. One
hypothesis is that a number of rare susceptibility variants of
large effect are segregating in the islands. Much evidence
has been presented in recent years to support the influence
of rare variants in MS risk, particularly among family
groups [33]. Within the Northern Isles, it is possible that
there are one or more rare variants, drifted to higher fre-
quency due to genetic simplification, possibly segregating
within families, that are associated with MS. Smaller con-
tributions will also be made from the high rates of over-
weight and obesity found in the islands. Orkney has the
highest percentage of individuals who are classed as over-
weight and obese for any location in Scotland at 73% (95%
CI 68, 78), while Shetland stands at 71% (95% CI 64, 77).
For comparison, the Scottish average is 65% (95% CI 64,
66) [34]. Obesity is a known risk factor for MS; a Men-
delian Randomisation study showed that an increase of
1 standard deviation in BMI increased the odds of devel-
oping MS by 41% (95% CI 20, 66) [8]. Additionally,
interactive effects have been shown between HLA-
DRB1*15:01 and obesity: individuals classed as obese who
carry HLA-DRB1*15 but not HLA-A*02 have an OR of
16.2 (95% CI 7.5, 35.2) for developing MS [35]. Given that
there are most likely multiple contributors to the excess rate
of MS in the Northern Isles, there are numerous avenues for
future research. The most obvious of these appears to be a
targeted search for rare variants. Whole-genome sequence
analysis has detected many Shetland-specific rare variants
[36]. The similar strong differentiation of Orkney in
genome-wide population genetic analyses [37] predicts a
similar situation there; however, power will always be
limited by the low absolute numbers of cases, overall and in
any particular kindred. The future of MS research in the
Northern Isles and beyond will lie in new methods to dis-
cover and explore the function of susceptibility variants and
their interactions with their unique environment. GWAS
summary statistics used to create the PRS and the raw PRS
for each study population can be found within the Edin-
burgh DataShare (https://doi.org/10.7488/ds/2992).
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